Modality
ADC
MOA
AuroraAi
Target
BTK
Pathway
DDR
Endometrial CaProstate CaFL
Development Pipeline
Preclinical
Jan 2018
→ May 2029
PreclinicalCurrent
NCT03237085
2,192 pts·Endometrial Ca
2018-01→2029-05·Completed
NCT03474716
2,063 pts·FL
2019-08→2028-07·Terminated
4,255 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-07-082.3y awayInterim· FL
2029-05-203.1y awayInterim· Endometrial Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
Preclinical
Complet…
Preclinical
Termina…
Catalysts
Interim
2028-07-08 · 2.3y away
FL
Interim
2029-05-20 · 3.1y away
Endometrial Ca
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03237085 | Preclinical | Endometrial Ca | Completed | 2192 | Biomarker |
| NCT03474716 | Preclinical | FL | Terminated | 2063 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |